Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Thomas Müller. (2013) Current status of safinamide for the drug portfolio of Parkinson’s disease therapy. Expert Review of Neurotherapeutics 13:9, pages 969-977.
Read now
Read now
Thomas Müller. (2010) New small molecules for the treatment of Parkinson's disease. Expert Opinion on Investigational Drugs 19:9, pages 1077-1086.
Read now
Read now
Antonio Di Stefano, Piera Sozio, Antonio Iannitelli & Laura Serafina Cerasa. (2009) New drug delivery strategies for improved Parkinson's disease therapy. Expert Opinion on Drug Delivery 6:4, pages 389-404.
Read now
Read now
Thomas Müller. (2008) Role of homocysteine in the treatment of Parkinson's disease. Expert Review of Neurotherapeutics 8:6, pages 957-967.
Read now
Read now
Thomas Müller & Hermann Russ. (2006) Levodopa, motor fluctuations and dyskinesia in Parkinson’s disease. Expert Opinion on Pharmacotherapy 7:13, pages 1715-1730.
Read now
Read now
Antonio Siniscalchi, Luca Gallelli, Nicola B. Mercuri, Guido Ferreri Ibbadu & Giovambattista De Sarro. (2006) Role of lifestyle factors on plasma homocysteine levels in Parkison's disease patients treated with levodopa. Nutritional Neuroscience 9:1-2, pages 11-16.
Read now
Read now
Articles from other publishers (18)
Linda Molteni, Bruno Charlier, Viviana Izzo, Albino Coglianese, Valeria Conti, Roberto Eleopra, Roberto Cilia, Chiara Capelli, Annachiara D’Urso & Ugo de Grazia. (2023) Development and Validation of a New LC-MS/MS Bioanalytical Method for the Simultaneous Determination of Levodopa, Levodopa Methyl Ester, and Carbidopa in Human Plasma Samples. Molecules 28:11, pages 4264.
Crossref
Crossref
Taiwo G. Olubodun-Obadun, Ismail O. Ishola & Olufunmilayo O. Adeyemi. (2022) Impact of environmental toxicants exposure on gut-brain axis in Parkinson disease. Drug Metabolism and Personalized Therapy 37:4, pages 329-336.
Crossref
Crossref
Valeria Conti, Viviana Izzo, Maria Claudia Russillo, Marina Picillo, Marianna Amboni, Cesa L. M. Scaglione, Alessandra Nicoletti, Ilaria Cani, Calogero E. Cicero, Emanuela De Bellis, Bruno Charlier, Valentina Giudice, Gerardina Somma, Graziamaria Corbi, Paolo Barone, Amelia Filippelli & Maria Teresa Pellecchia. (2022) Gender Differences in Levodopa Pharmacokinetics in Levodopa-Naïve Patients With Parkinson’s Disease. Frontiers in Medicine 9.
Crossref
Crossref
Ziqiang Li, Xiuqi Bao, Xiaoguang Bai, Guoning Zhang, Juxian Wang, Mei Zhu, Yue Wang, Junmei Shang, Chanjuan Sheng, Dan Zhang & Yucheng Wang. (2019) Design, Synthesis, and Biological Evaluation of Phenol Bioisosteric Analogues of 3-Hydroxymorphinan. Scientific Reports 9:1.
Crossref
Crossref
N. Nevalainen, S. af Bjerkén, G.A. Gerhardt & I. Strömberg. (2014) Serotonergic nerve fibers in l-DOPA-derived dopamine release and dyskinesia. Neuroscience 260, pages 73-86.
Crossref
Crossref
Thomas Müller. (2012) Drug therapy in patients with Parkinson’s disease. Translational Neurodegeneration 1:1.
Crossref
Crossref
Thomas Müller, Manfred Gerlach, Moussa B.H. Youdim & Peter Riederer. 2012. Neurobiology of Psychiatric Disorders. Neurobiology of Psychiatric Disorders
477
490
.
Thomas Müller. (2010) The Impact of COMT-inhibition on Gastrointestinal Levodopa Absorption in Patients with Parkinson's Disease. Clinical Medicine Insights: Therapeutics 2, pages CMT.S1169.
Crossref
Crossref
Thomas Müller. 2010. Basic Aspects of Catechol-O-Methyltransferase and the Clinical Applications of its Inhibitors. Basic Aspects of Catechol-O-Methyltransferase and the Clinical Applications of its Inhibitors
49
71
.
Thomas Müller & Wilfried Kuhn. (2007) Neurotoxicity of levodopa: treatment-associated homocysteine increase. Nature Clinical Practice Neurology 3:6, pages E1-E1.
Crossref
Crossref
T. Müller. 2007. Handbook of Neurochemistry and Molecular Neurobiology. Handbook of Neurochemistry and Molecular Neurobiology
103
121
.
Thomas Müller. (2006) Tolcapone in the management of Parkinson’s disease. Aging Health 2:5, pages 709-720.
Crossref
Crossref
Dirk Woitalla, Oliver Goetze, Jeong I. Kim, Alice B. Nikodem, Wolfgang E. Schmidt, Horst Przuntek & Thomas Müller. (2006) Levodopa availability improves with progression of Parkinson’s disease. Journal of Neurology 253:9, pages 1221-1226.
Crossref
Crossref
Wei Zhang, Liya Qin, Tongguang Wang, Sung-Jen Wei, Hui-Ming Gao, Jie Liu, Belinda Wilson, Bin Liu, Wanqin Zhang, Hyoung-Chun Kim & Jau-Shyong Hong. (2004) 3‐Hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS‐induced neurotoxicity. The FASEB Journal 19:3, pages 1-25.
Crossref
Crossref
Thomas M??ller, Birgit Vo, Kerstin Hellwig, Franz Josef Stein, Thorsten Schulte & Horst Przuntek. (2004) Treatment Benefit and Daily Drug Costs Associated with Treating Parkinson???s Disease in a Parkinson???s Disease Clinic. CNS Drugs 18:2, pages 105-111.
Crossref
Crossref
D. Woitalla, W. Kuhn & T. Müller. 2004. Focus on Extrapyramidal Dysfunction. Focus on Extrapyramidal Dysfunction
15
20
.
D. Woitalla, T. Müller, S. Benz, R. Horowski & H. Przuntek. 2004. Focus on Extrapyramidal Dysfunction. Focus on Extrapyramidal Dysfunction
89
95
.
Bin Liu, Hui-Ming Gao & Jau-Shyong Hong. (2003) Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation.. Environmental Health Perspectives 111:8, pages 1065-1073.
Crossref
Crossref